Skip to main content
Nature Portfolio logoLink to Nature Portfolio
. 2026 Aug 14;16:37937. doi: 10.1038/s41598-026-66542-w

Linking surfactant proteins and genetic variants to COVID-19 severity

Brycen Aldrich 1, Natalie Sicher 1, Shaoyi Zhang 2, Lauren Mazur 1,3, Catherine M Roberts 1,4, Erik Lehman 2, Dajiang Liu 2, Chintan K Gandhi 1,✉
PMCID: PMC13759313

Abstract

COVID-19 presents with variable clinical severity. Surfactant proteins (SPs) are critical to lung function and host defense, but their role as biomarkers for COVID-19 severity, and the impact of SP genetic variants, remains unclear. Therefore, we asked whether plasma SP levels and SP genetic variants are associated with COVID-19 severity in adults. We conducted a cohort study of 261 adults with PCR-confirmed COVID-19, classified as non-severe (n = 117) or severe (n = 144) based on WHO severity criteria. Plasma SP-A, SP-B, and SP-D levels were measured. Genetic variants in SFTPA1, SFTPA2, SFTPB, SFTPC, and SFTPD were analyzed. Quantile regression, receiver operating curve analysis, and logistic regression were used to assess associations. To compare model performance, the corrected Akaike Information Criterion (AICC) was used. Mediation analysis evaluated interactions among SP-A levels, genetic variant and disease severity. Severe COVID-19 was associated with higher plasma SP-A (9.8 vs. 8.4 ng/mL, p = 0.04) and SP-B (4119.2 vs. 3137.2 ng/mL, p = 0.01) levels, but not SP-D. SP-A and SP-B showed moderate predictive value for severity (AUC = 0.71). Inclusion of plasma SP-A (AICC = 219.7) or SP-B (AICC = 221.0) levels along with demographics improved performance over the demographics-only model (AICC = 300.2). Although significance was lost after Bonferroni correction, rs10351 in SFTPA1 was associated with lower risk of severe disease (OR = 0.40, p = 0.03); and lower SP-A level. Mediation analysis suggested the association was driven by disease severity. No associations were found for other SP gene variants. Elevated SP-A and SP-B levels are associated with severe COVID-19 and may serve as biomarkers. Predictive models combining either SP-A or SP-B levels with clinical information offer strong potential for risk stratification. The SFTPA1 variant rs10351 may confer protection through reduced alveolar injury, though further validation is warranted.

Clinical trial registration: ClinicalTrials.gov. Study ID# NCT04650191, 30th November, 2020.

Keywords: Biomarkers, COVID-19 severity, Surfactant proteins, Surfactant protein genetic variants

Subject terms: Biomarkers, Diseases, Genetics, Medical research

Introduction

The emergence of novel coronavirus disease (COVID-19) at the end of 2019 sparked an unprecedented global pandemic1, infecting over 770 million people and causing more than 7 million deaths worldwide, including 1.2 million in the United States2. Although infection and mortality rates have declined, the pandemic continues to have lasting economic and public health consequences. COVID-19 exhibits wide clinical variability—from asymptomatic infection to respiratory failure and death—with more severe disease in adults3. Known risk factors such as old age, male and obesity contribute to disease severity4, but do not fully explain heterogeneity in outcomes. Growing evidence highlights the critical role of host genetic factors in influencing disease susceptibility and severity5. Genome-wide association studies have identified genetic variants that modulate individual response to infection6,7. Understanding these genetic factors is critical for identifying at-risk individuals and guiding precision medicine approaches.

Pulmonary surfactant, secreted by alveolar type II cells, is essential for alveolar stability and gas exchange8. It consists of lipids and four surfactant proteins (SP)-A, SP-B, SP-C, and SP-D. The hydrophobic proteins, SP-B and SP-C, reduce surface tension, whereas, the hydrophilic proteins, SP-A and SP-D, support immune defense and pathogen clearance9,10. These functions become especially relevant during pulmonary infections such as COVID-1911, influenzae12 and respiratory syncytial virus13. SP-A is encoded by two genes, SFTPA1 and SFTPA2, while SP-B, SP-C and SP-D are each encoded by a single genes, SFTPB, SFTPC and SFTPD, respectively14–16. Surfactant protein gene polymorphisms are associated with various acute and chronic respiratory illnesses17–21, including but not limited to neonatal respiratory distress syndrome22, respiratory syncytial virus23–25, cystic fibrosis26, and idiopathic pulmonary fibrosis17. More importantly, we recently demonstrated that higher levels of SP-A are associated with COVID-19 severity in children, however, we did not observe a direct association of SP genetic variants and disease severity in that cohort27.

Based on these findings, we hypothesized that SP genetic variants may play a more prominent role in adults with COVID-19 severity, and that the plasma surfactant protein levels are elevated in patients with severe disease. Investigating these associations may shed light on mechanisms driving COVID-19 outcomes and help identify novel prognostic biomarkers and targeted therapies.

Methods

Study population

This study was conducted using remnant clinical specimens and de-identified clinical data obtained through an Institutional Review Board-approved COVID-19 biorepository at Penn State Health. Adult patients (≥ 18 years) with PCR-confirmed COVID-19 infection who received care at Milton S. Hershey Medical Center during 2020 were eligible. Remnant blood specimens remaining after routine clinical laboratory testing were collected by the clinical laboratory under the biorepository protocol and stored for future research. Plasma was available for 194 of the 261 eligible patients. Demographic and clinical data were obtained from de-identified electronic medical records through the honest broker system. The study was approved by the Penn State College of Medicine Institutional Review Board (Study #15456), which determined that the study qualified for exempt status and waived the requirement for informed consent because only remnant clinical specimens and existing de-identified clinical data were used.

Classification of subjects

Patients were classified according to World Health Organization (WHO) COVID-19 severity criteria into non-severe and severe/critical disease categories28. Severe COVID-19 was defined by the presence of any of the following: oxygen saturation < 90% on room air, signs of severe respiratory distress (including tachypnea, use of accessory muscles, or inability to speak full sentences), requirement for supplemental oxygen, or radiographic evidence of severe pneumonia. Critical disease was defined as requiring intensive care unit admission and/or life-sustaining interventions, including mechanical ventilation (invasive or non-invasive) or vasopressor support. Non-severe COVID-19 was defined as the absence of criteria for severe or critical illness. For analytical purposes, individuals with non-severe disease, including those managed as outpatients or those incidentally admitted for reasons unrelated to COVID-19, were grouped as controls. Patients meeting WHO criteria for severe or critical COVID-19 requiring hospitalization due to respiratory compromise were classified as cases. Severe and critical disease categories were combined for analysis due to the small number of patients in each individual category.

Surfactant protein concentration

Plasma concentrations of SP-A, SP-B, (Novus Biologicals, LLC, Centennial, CO) and SP-D (Invitrogen, Life Technologies Corporation, Carlsbad, CA) were quantified using enzyme-linked immunosorbent assay kits according to the manufacturers’ protocols27. Samples were tested in duplicates, and data were included only if the coefficient of variation was ≤ 10%. SP-C (Biomatik Corporations, Wilmington, DE, USA) levels were below detectable limits (0.312–20 ng/ml) in plasma samples and excluded from analysis. This is likely because SP-C is a highly hydrophobic surfactant protein that remains primarily localized within the alveolar compartment, resulting in very low circulating plasma levels in our cohort.

DNA isolation and genotyping

Genomic DNA was extracted from blood using the QIAamp Blood Kit, per manufacturer’s protocol23,29. Targeted sequencing of SFTPA1, SFTPA2, SFTPB, SFTPC, and SFTPD was performed using custom Ampliseq panels designed by Illumina, as previously described23. SP-A1 (6A and 6Am, m = 0–13) and SP-A2 (1A and 1An, n = 0–15) genotypes were assigned29.

All samples were anonymized using unique numerical identifiers. Laboratory personnel performing SP measurements and genotyping were blinded to clinical outcomes to minimize bias.

Statistical analysis

The distribution of study variables was assessed prior to formal analyses. Two-sample t-tests and Chi-square tests were used to compare demographics between severity groups. Quantile regression was performed to compare median SP levels between groups in both unadjusted and adjusted analyses. Adjusted models included age30–32, sex33, smoking history34, and asthma35 based on prior evidence demonstrating associations between these factors and circulating SP levels. Receiver operating characteristic (ROC) curves evaluated the diagnostic utility of plasma SP-A and SP-B levels to discriminate between non-severe and severe COVID-19. The Youden Index (J = sensitivity + specificity − 1) was applied to identify the optimal cutoff value for each biomarker. This approach selects the threshold that maximizes the combined sensitivity and specificity, thereby providing the best overall discrimination between groups. The resulting optimal cutoffs were converted into binary variables and included as predictors in logistic regression models adjusted for age, sex, history of smoking and asthma. Odds ratios (ORs) and 95% confidence intervals (CIs) were reported. To assess the fit of the unadjusted and adjusted models in relation to one another, we used the corrected Akaike Information Criterion (AICC) to compare the models with various predictors including a model with both SP-A and SP-B cut-offs included as predictors and a model with only the demographic covariates included. The model with the lowest AICC was deemed the best. Analyses were performed using SAS v9.4 (SAS Institute), with significance set at p < 0.05.

Genetic association analysis

Associations between individual single nucleotide polymorphisms (SNPs) and COVID-19 severity were assessed using logistic regression models in PLINK 2.0. Each SNP was analyzed independently, with adjustment for age, sex (male as reference), and self-identified race. Race was modeled using a series of categorical indicator variables corresponding to: Declined to answer (0), White (1), Black (2), Asian (3), Mixed (4), Other (5), and Native Hawaiian or Pacific Islander (6). Additional adjustment for comorbid conditions was not performed because of the modest sample size, the risk of model overfitting, and the substantial collinearity of these variables with age and sex. ORs and p-values were reported. Bonferroni correction adjusted for multiple comparisons. Analyses were conducted in R v4.3.336.

Association of SNP with surfactant protein levels

We conducted linear regression analyses to examine the relationship between rs10351 of the SFTPA1 (which was associated with COVID-19 severity, as described below) and plasma SP-A levels adjusting for age, sex, and race using R version 4.3.336. Adjusted mean difference in SP-A levels between groups was calculated with corresponding p-values.

Mediation analysis

To assess whether COVID-19 severity mediated the relationship between rs10351 and SP-A levels, we conducted causal mediation analysis using the ‘mediation’ package in R (version 4.3.3)37 with the following approach: First, we fitted a logistic regression model with disease severity as the outcome and rs10351 as the predictor, adjusted for age, sex, and race (mediator model). Second, we fitted a linear regression model with SP-A plasma levels as the outcome, including both rs10351 and disease severity as predictors along with the same covariates (outcome model). We then performed bootstrapped mediation analysis (1,000 iterations) to estimate: (1) the average causal mediation effect—the indirect effect of rs10351 on SP-A levels through disease severity; (2) the average direct effect—the effect of rs10351 on SP-A levels independent of disease severity; (3) the total effect; and (4) the proportion of the total effect that is mediated. Statistical significance was assessed using bootstrapped confidence intervals.

In accordance with the Declaration of Helsinki, the study was approved by the Human Subjects Protection Office and the Institutional Review Board (Study ID#15456) at Penn State College of Medicine. The IRB determined that the study qualified for exempt status. The requirement for informed consent was waived because the study utilized remnant clinical specimens and existing de-identified clinical data collected during routine clinical care.

Results

Subject characteristics

Among 261 adults with confirmed COVID-19, 117 (45%) had non-severe and 144 (55%) had severe disease according to WHO criteria (Table 1). Participants with severe disease were significantly older and more likely to be male. Race and ethnicity distributions did not differ significantly between groups. A higher proportion of severe cases were former smokers, though current smoking status was similar (p = 0.89). Comorbidities such as hypertension, diabetes, hyperlipidemia, asthma, heart failure, and chronic kidney disease were more prevalent in the severe group.

Table 1.

Demographics of the cohort stratified by non-severe and severe coronavirus disease.

Variable Whole cohort
(n = 261)
Non-severe
(n = 117)
Severe
(n = 144)
p value
Demographics
 Age on admission(years) 58.7 ± 20 48.9 ± 19.6 66.6 ± 16.6  < 0.001
 Female (%) 157 (60) 79 (68) 78 (54) 0.03
 White race (%) 164 (63) 68 (59) 96 (67) 0.18
 Hispanic ethnicity (%) 46 (18) 23 (20) 23 (16) 0.42
Current smoker 2 1 1 0.89
Past smoker (%) 20 (8) 5 (4) 15 (10) 0.05
Past medical history (%)
 Hypertension 120 (46) 40 (34) 80 (56)  < 0.001
 Diabetes 85 (32) 31 (26) 54 (38) 0.05
 Hyperlipidemia 75 (29) 19 (16) 56 (39)  < 0.001
 Asthma 27 (10) 7 (6) 20 (14) 0.02
 Heart failure 26 (10) 7 (6) 19 (13) 0.05
 Chronic kidney disease 26 (10) 6 (5) 20 (14) 0.02
 Stroke 19 (7) 9 (8) 10 (7) 0.86
 Cancer 30 (12) 12 (10) 18 (13) 0.5
Hospital days 7.2 ± 12.6 1.7 ± 6.8 11.7 ± 14.3  < 0.001
Admission to ICU (%) 41 (16) 4 (3) 37 (26)  < 0.001
Ventilator days 1.1 ± 6 0 2.1 ± 8 0.006
Respiratory support (%)
 Nasal cannula 91 (35) 4 (3) 87 (60)  < 0.001
 Non-invasive (HFNC/CPAP/BiPAP) 48 (18) 1 (1) 47 (33)  < 0.001
 Invasive support 19 (7) 0 19 (13)  < 0.001
Medication use (%)
 Steroids 38 (14) 3 (3) 35 (24)  < 0.001
 Antibiotics 75 (29) 19 (16) 56 (39)  < 0.001
 Remdesivir 64 (24) 0 64 (44)  < 0.001
 Doxycycline 35 (13) 8 (7) 27 (19)  < 0.001
 Hydroxychloroquine 17 (6) 1 (1) 16 (11)  < 0.001
 Vasopressors 13 (5) 0 13 (9) 0.001
 Plasma therapy 5 (2) 0 5 (4) 0.04
Prone position (%) 14 (5) 1 (1) 13 (9) 0.003
Acute kidney injury (%) 39 (15) 6 (5) 33 (23)  < 0.001
Outcomes (%)
 Mortality 15 (6) 0 15 (11)  < 0.001
 Rehabilitation/Long term care 24 (9) 4 (3) 20 (14) 0.003
 Tracheostomy 1 0 1
 ECMO 1 0 1

Mean ± SD.

As expected, patients with severe COVID-19 experienced significantly longer hospital stays, higher ICU admissions, and more ventilator support. Respiratory support was more frequently needed in the severe group, including nasal cannula, non-invasive ventilation (HFNC, CPAP, BiPAP), and invasive ventilation. Severe cases were more often treated with steroids, antibiotics, remdesivir, doxycycline, hydroxychloroquine, and vasopressors. Plasma therapy use was rare but more common in severe cases. Severe cases had higher mortality and were more likely to require rehabilitation or long-term care after discharge. Tracheostomy and ECMO occurred exclusively in the severe group.

Plasma surfactant protein levels

Plasma SP-A and SP-B levels were significantly higher in adults with severe disease (Fig. 1, Table 2). After adjusting for potential confounders including age, sex, smoking history, and asthma, median SP-A levels were 9.8 ng/mL in the severe group versus 8.4 ng/mL in the non-severe group (p = 0.04). SP-B levels were also elevated: 4119.2 ng/mL vs. 3137.2 ng/mL (p = 0.01). No significant difference was found for SP-D levels (p = 0.29).

Fig. 1.

Fig. 1

Elevated plasma SP-A and SP-B levels (ng/mL) in adults with severe COVID-19. Box plots depicting plasma concentrations of (A) SP-A and (B) SP-B in adults with non-severe (red) and severe (blue) COVID-19. Individuals with severe disease exhibited significantly higher levels of both SP-A and SP-B compared to those with non-severe disease (p < 0.05). In each plot, the box represents the interquartile range (IQR) from the 25th to the 75th percentile, with the horizontal line indicating the median and the symbol (dot or plus) representing the mean. Whiskers extend to 1.5 × the IQR, and values beyond this range are plotted as individual outliers.

Table 2.

Plasma surfactant protein (SP)-A, -B and -D levels in adults with non-severe and severe COVID-19 after adjusting for age, sex, history of smoking and asthma.

Plasma SPs (ng/ml) Severe disease (median, 95% CI) Non-severe disease (median, 95% CI) p value
SP-A 9.8 (8.4, 11.1) 8.4 (6.9, 9.9) 0.04
SP-B 4119.2 (3591.4, 4647.1) 3137.2 (2365.5, 3908.9) 0.01
SP-D 10.86 (6.39, 15.33) 8.29 (2.75, 13.83) 0.29

CI, Confidence interval.

Using receiver operating characteristic curve analysis, a plasma SP-A cutoff of ≥ 8.7 ng/mL yielded 63% sensitivity, 70% specificity, and an AUC of 0.71 (Fig. 2). Logistic regression, adjusted for age, sex and asthma, showed that SP-A ≥ 8.7 ng/mL was associated with over fourfold increased odds of severe disease (OR: 4.2; 95% CI: 2.2–7.7; p < 0.001). SP-B ≥ 3427 ng/mL predicted severity with 76% sensitivity, 60% specificity, AUC of 0.63, and an adjusted OR of 5.4 (95% CI: 2.8–10.3; p < 0.001).

Fig. 2.

Fig. 2

Receiver operating characteristic curve of the plasma SP-A and SP-B levels predicting severe COVID-19.

Next, we compared different models using AICC to predict COVID-19 severity (Table 3). We found that the demographics-only model (AICC = 300.2) had the poorest fit. Inclusion of plasma SP levels improved model performance, with the SP-B model (AICC = 243.7) outperforming SP-A alone (AICC = 249.5). Adjusting for demographics further enhanced model fit, and the combined model including both SP-A and SP-B levels along with age, sex, and asthma history (Model 6; AICC = 216.1) provided the best overall fit.

Table 3.

Comparison of logistic regression models predicting COVID-19 severity using demographics and surfactant protein levels.

Models Corrected Akaike information criterion
Model 1: Clinical demographics (age, sex, history of smoking and asthma) 300.2
Model 2: SP-A cut-off only 249.5
Model 3: SP-A cut-off + clinical demographics 219.7
Model 4: SP-B cut-off only 243.7
Model 5: SP-B cut-off + clinical demographics 221.0
Model 6: SP-A + SP-B cut-offs + clinical demographics 216.1

Association of SP genetic variants with COVID-19 severity

In unadjusted analyses, rs10351 (SFTPA1) was associated with decreased risk of severe COVID-19 (OR = 0.4; p = 0.03), and rs911886 (SFTPD) with increased risk (OR = 2.5; p = 0.03). However, these did not remain significant after Bonferroni correction. No significant associations were observed for SFTPA2, SFTPB, SFTPC, or SP-A1/SP-A2 genotypes.

Given that rs10351 of the SFTPA1 was associated with reduced COVID-19 severity and that elevated SP-A levels were observed in severe disease, we further examined the relationship among rs10351, plasma SP-A levels, and disease severity. Linear regression analysis showed that rs10351 was significantly associated with lower SP-A levels, with an adjusted mean difference of − 4.7 ng/mL (p = 0.006). Mediation analysis revealed that disease severity significantly mediated the relationship between rs10351 and SP-A levels. The total effect of rs10351 on SP-A levels, before accounting for mediation, was statistically significant (p = 0.03). However, the direct effect of rs10351 on SP-A levels became non-significant when accounting for disease severity as a mediator (p = 0.07), while the indirect effect through severity was significant (p = 0.022). These findings suggest that rs10351 may influence SP-A levels through its impact on COVID-19 severity.

Discussion

The current study examined surfactant protein (SP) levels and genetic variants as potential biomarkers for severe COVID-19 in adults. Given the heterogeneous clinical presentation of COVID-19, reliable predictors of severity are essential. Our findings show that elevated plasma levels of SP-A and SP-B—but not SP-D—are significantly associated with severe disease. Additionally, we identified a SFTPA1 variant (rs10351) associated with lower risk of severe COVID-19 in unadjusted analysis. Mediation analysis suggests that this protective effect may be mediated through reduced SP-A leakage, possibly reflecting less alveolar injury. A SFTPD variant (rs911886) was also associated with increased risk before correction. No significant associations were observed for SFTPA2, SFTPB, or SFTPC variants.

Consistent with prior studies38,39, older age, male sex, and comorbidities such as hypertension, diabetes, and chronic lung or kidney disease were associated with severe illness, supporting the generalizability of our cohort. We also observed significantly higher plasma levels of SP-A and SP-B—but not SP-D—in adults with severe disease. This contrasts with prior studies in adults, which reported elevated serum SP-D, but not SP-A, in severe COVID-1940,41. Notably, Maddaloni et al. reported much lower serum SP-A levels (0.09–0.12 ng/mL), whereas our study found considerably higher plasma concentrations (median 9.8 ng/mL in severe cases vs. 8.4 ng/mL in non-severe cases). These differences may be explained by differences in sample type (plasma vs. serum), disease severity, and/or sample size (n = 194 in our study vs. n = 51 in Maddaloni’s). SP-A is a well-established marker of lung injury and innate immune activity9,10, and its systemic elevation in our cohort is consistent with findings in other respiratory diseases31,42. We also report elevated plasma SP-B levels—a novel observation, as systemic SP-B has not previously been studied in the context of COVID-19. Previously, we showed elevated SP-A—but not SP-B or SP-D—in children with severe COVID-1927, suggesting potential age-related differences in surfactant responses30,32,43. The elevated plasma SP-A and SP-B levels observed in our adult cohort likely reflect alveolar-capillary barrier disruption and subsequent protein leakage into the circulation after COVID-19 infection, a pattern also seen in other forms of lung injury44–49. Larger, multicenter studies are needed to validate these findings, and further research is warranted to clarify the underlying mechanisms and the precise role of SPs in systemic circulation during severe COVID-19 infection.

We identified plasma thresholds of ≥ 8.7 ng/mL for SP-A and ≥ 3400 ng/mL for SP-B as moderately accurate predictors of COVID-19 severity, each achieving an AUC of 0.71. While this level of discrimination is considered acceptable, integration with clinical variables further improved predictive performance. As shown in Table 3, models combining either SP-A (Model 3; AICC = 219.7) or SP-B (Model 5; AICC = 221.0) with demographics outperformed models using clinical data alone (Model 1; AICC = 300.2) or protein markers alone (Models 2 and 4). Although the full model incorporating both SP-A and SP-B with demographics (Model 6; AICC = 216.1) provided the best fit, the marginal gain over Models 3 and 5 suggests that in practical clinical settings, measurement of either SP-A or SP-B alongside basic clinical information may be sufficient for risk stratification. These findings support the potential utility of plasma SP-A and SP-B levels as accessible blood-based biomarkers of COVID-19 severity, pending further validation in larger, diverse populations.

We further investigated whether SP gene variants are associated with COVID-19 severity and identified two SNPs—rs10351 in SFTPA1 and rs911886 in SFTPD—that are associated with decreased and increased risk of severe disease, respectively, prior to Bonferroni correction. Notably, rs10351 is a synonymous variant in SFTPA1 that has not been previously linked to lung disease. However, our mediation analysis revealed that this SNP is associated with reduced plasma SP-A levels only in the presence of COVID-19, suggesting it may function as a context-dependent or “latent” variant whose effects are triggered by environmental stress, such as viral infection. We speculate that rs10351 may help preserve alveolar-capillary barrier integrity during infection, thereby limiting SP-A leakage, however, the exact underlying mechanisms remain unclear. Together, these findings suggest that rs10351 in SFTPA1 may exert a protective effect against severe COVID-19, and that its influence on plasma SP-A levels is likely mediated through its effect on disease severity. Although we did not conduct functional studies of particular SNPs, prior research—including ours—has shown that common SFTPA1 variants can influence surfactant protein expression, polymerization, and function in vitro and in vivo15,16,50,51. Future work using rs10351-specific constructs in cell lines or transgenic models would clarify its role.

We found no significant associations between COVID-19 severity and other SP gene variants (SFTPA2, SFTPB, SFTPC) or SP-A1/SP-A2 haplotypes. This could be due to either limited statistical power to detect small effect sizes and/or our study design, which included only COVID-19–positive individuals and used non-severe cases as controls. Although this design may reduce the likelihood of detecting associations seen in case–control studies with uninfected individuals, it aligns better with the clinical goal of identifying susceptible individuals after COVID-19 infection. Identifying genetic markers of severity—not just susceptibility—could help guide early interventions and allocate resources more effectively.

A major strength of our study is its size—the largest to date investigating systemic SP levels in adult COVID-19. We adjusted relevant confounders and used a real-world cohort, enhancing generalizability. If validated in larger studies, these findings could support early identification and management of high-risk patients. Our study has several limitations. First, we did not collect BAL samples, which would more directly reflect the local lung environment. However, BAL collection is invasive and often impractical in clinical settings, particularly during a pandemic. In contrast, plasma surfactant protein measurements offer a non-invasive alternative that may serve as a useful proxy for pulmonary injury and could support diagnostic and prognostic decision-making. Second, although our sample size is relatively large for a clinical study, it may still lack the statistical power required to detect genetic associations, especially given the small effect sizes of individual SNPs, the burden of multiple testing, and potential interactions with other genetic or environmental factors. Another limitation relates to the composition of the non-severe group. During the early phase of the pandemic, universal COVID-19 screening was routinely performed for hospital admissions and procedures, resulting in inclusion of some individuals who were asymptomatic or incidentally found to be COVID-19 positive while admitted for unrelated medical or surgical reasons. Although patients were classified according to WHO severity criteria, the non-severe group likely represented a heterogeneous population that included asymptomatic and mildly symptomatic individuals. This heterogeneity may have reduced the observed differences in plasma SP levels between non-severe and severe groups and potentially biased results toward the null. Consequently, the true differences in SP levels between clinically symptomatic mild disease and severe disease may be even greater than those observed in this study. An additional limitation is the inability to determine the specific stage of COVID-19 at which patients presented to the medical facility or when biospecimens were collected. This variability may have influenced SP levels, making it difficult to interpret their relationship to disease progression. Future studies should investigate how SP levels fluctuate or progress throughout the course of infection to better understand their clinical utility as biomarkers. Additionally, while all samples were collected during the first six months of the pandemic—before the emergence of major SARS-CoV-2 variants—we did not genotype viral strains. The lack of variant information may limit the generalizability of our findings, as different variants could influence disease severity and clinical presentation. Finally, although we identified rs10351 in SFTPA1 as a potential protective factor against severe COVID-19, external validation is essential. Follow-up studies, including functional analyses, are needed to clarify the biological relevance of this variant and its potential role in modulating disease severity.

Conclusion

This study represents the largest investigation to date examining the association between SP levels and COVID-19 severity. We found that plasma levels of SP-A and SP-B—but not SP-D—were significantly elevated in severe cases, supporting their potential as non-invasive biomarkers for disease severity. Additionally, rs10351 of the SFTPA1 may offer protection against severe COVID-19, likely through its effect on reducing SP-A levels via decreased alveolar epithelial injury. While further functional studies and external validation are needed, our findings offer insight into surfactant biology in COVID-19 and lay the groundwork for future research into molecular predictors of disease severity.

Acknowledgements

The authors thank the study participants.

Abbreviations

AUC

Area under the curve

CIs

Confidence intervals

COVID-19

Coronavirus

OR

Odds ratio

SP

Surfactant protein

Author contributions

Conceived and designed research: BA, NS, CKG; performed experiments: BA, NS, BA, LM, CMR, CKG; analyzed data: SZ, EL, DL, CKG; interpreted results of experiments: BA, NS, SZ, EL, CKG; prepared figures, drafted manuscript: BA, NS, CKG; edited and revised manuscript: BA, DL, CKG; approved final version of manuscript: BA, NS, SZ, LM, CMR, EH, DL, CKG.

Funding

The National Institute of Health (NIH), K08HL169727 and H.G. Barsumian Trust grant to CKG.

Data availability

The data presented in the study have been deposited in the ClinVar repository, accession number SCV002506610. Clinical data will be made available upon reasonable request.

Declarations

Competing interests

The authors declare that the research conducted was in the absence of any commercial or financial relationships construed as a potential conflict of interest.

Footnotes

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  • 1.Chung, Y.-S., Lam, C.-Y., Tan, P.-H., Tsang, H.-F. & Wong, S.-C.C. Comprehensive review of COVID-19: Epidemiology, pathogenesis, advancement in diagnostic and detection techniques, and post-pandemic treatment strategies. Int. J. Mol. Sci.25, 8155 (2024). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.W. H. O. (WHO). WHO Coronavirus (COVID-19) dashboard > Cases [Dashboard]. https://data.who.int/dashboards/covid19/cases (2023).
  • 3.Mentor, G. et al. The effect of age and comorbidities: Children vs adults in their response to SARS-CoV-2 infection. Viruses 10.3390/v16050801 (2024). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Docherty, A. B. et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ369, m1985. 10.1136/bmj.m1985 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Mapping the human genetic architecture of COVID-19. Nature600, 472–477. 10.1038/s41586-021-03767-x (2021). [DOI] [PMC free article] [PubMed]
  • 6.Pairo-Castineira, E. et al. GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19. Nature617, 764–768. 10.1038/s41586-023-06034-3 (2023). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Lammi, V. et al. Genome-wide association study of long COVID. Nat. Genet. 10.1038/s41588-025-02100-w (2025). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Nayak, A., Dodagatta-Marri, E., Tsolaki, A. G. & Kishore, U. An Insight into the diverse roles of surfactant proteins, SP-A and SP-D in innate and adaptive immunity. Front. Immunol.3, 131. 10.3389/fimmu.2012.00131 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Kishore, U. et al. Surfactant proteins SP-A and SP-D: structure, function and receptors. Mol Immunol43, 1293–1315. 10.1016/j.molimm.2005.08.004 (2006). [DOI] [PubMed] [Google Scholar]
  • 10.Wright, J. R. Immunoregulatory functions of surfactant proteins. Nat. Rev. Immunol.5, 58–68. 10.1038/nri1528 (2005). [DOI] [PubMed] [Google Scholar]
  • 11.Bastani, M. N. & Jalilian, S. Unraveling the enigma: The emerging significance of pulmonary surfactant proteins in predicting, diagnosing, and managing COVID-19. Immun. Inflamm. Dis.12, e1302. 10.1002/iid3.1302 (2024). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Yau, E. et al. Surfactant protein A alters endosomal trafficking of influenza A virus in macrophages. Front. Immunol.14, 919800. 10.3389/fimmu.2023.919800 (2023). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Mapindra, M. P., Castillo-Hernandez, T., Clark, H. & Madsen, J. Surfactant Protein-A and its immunomodulatory roles in infant respiratory syncytial virus infection: A potential for therapeutic intervention?. Am. J. Physiol.-Lung Cell. Mol. Physiol.328, L179–L196. 10.1152/ajplung.00199.2024 (2025). [DOI] [PubMed] [Google Scholar]
  • 14.Depicolzuane, L., Phelps, D. S. & Floros, J. Surfactant protein-A function: Knowledge gained from SP-A knockout mice. Front. Pediatr.9, 799693. 10.3389/fped.2021.799693 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Floros, J., Thorenoor, N., Tsotakos, N. & Phelps, D. S. Human surfactant protein SP-A1 and SP-A2 variants differentially affect the alveolar microenvironment, surfactant structure, regulation and function of the alveolar macrophage, and animal and human survival under various conditions. Front. Immunol.12, 681639. 10.3389/fimmu.2021.681639 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Floros, J. & Tsotakos, N. Differential regulation of human surfactant protein A genes, SFTPA1 and SFTPA2, and their corresponding variants. Front. Immunol.12, 766719. 10.3389/fimmu.2021.766719 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Abbasi, A. et al. Single nucleotide polymorphisms (SNP) and SNP-SNP interactions of the surfactant protein genes are associated with idiopathic pulmonary fibrosis in a Mexican study group; Comparison with hypersensitivity pneumonitis. Front. Immunol.13, 842745. 10.3389/fimmu.2022.842745 (2022). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Gandhi, C. K. et al. SNP and haplotype interaction models reveal association of surfactant protein gene polymorphisms with hypersensitivity pneumonitis of Mexican population. Front. Med. 10.3389/fmed.2020.588404 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Gandhi, C. K. et al. Association of SNP–SNP interactions of surfactant protein genes with pediatric acute respiratory failure. J. Clin. Med.9, 1183 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Gandhi, C. K. et al. SNP–SNP interactions of surfactant protein genes in persistent respiratory morbidity susceptibility in previously healthy children. Front. Genet. 10.3389/fgene.2022.815727 (2022). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Emery, L. et al. Association of surfactant protein A2 with acute respiratory failure in children. Pediatr. Int.65, e15672. 10.1111/ped.15672 (2023). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Amatya, S. et al. Single nucleotide polymorphisms interactions of the surfactant protein genes associated with respiratory distress syndrome susceptibility in preterm infants. Front. Pediatr.9, 682160. 10.3389/fped.2021.682160 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Depicolzuane, L. C. et al. Hydrophilic but not hydrophobic surfactant protein genetic variants are associated with severe acute respiratory syncytial virus infection in children. Front. Immunol. 10.3389/fimmu.2022.922956 (2022). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Thomas, N. J. et al. Transmission of surfactant protein variants and haplotypes in children hospitalized with respiratory syncytial virus. Pediatr. Res.66, 70–73. 10.1203/PDR.0b013e3181a1d768 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Gandhi, C. K. et al. Association of SNP-SNP interactions of surfactant protein genes with severity of respiratory syncytial virus infection in children. Physiol. Genomics56, 691–697. 10.1152/physiolgenomics.00045.2024 (2024). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Lin, Z. et al. Genetic association of pulmonary surfactant protein genes, SFTPA1, SFTPA2, SFTPB, SFTPC, and SFTPD with cystic fibrosis. Front. Immunol.9, 2256. 10.3389/fimmu.2018.02256 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Sicher, N. et al. Surfactant protein levels and genetic variants as biomarkers for COVID-19 severity in children. Am. J. Physiol. Lung Cell. Mol. Physiol.328, 350–356. 10.1152/ajplung.00318.2024 (2025). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.World Health Organization. Clinical management of COVID-19: Interim guidance, 27 May 2020. (World Health Organization, 2020).
  • 29.DiAngelo, S. et al. Novel, non-radioactive, simple and multiplex PCR-cRFLP methods for genotyping human SP-A and SP-D marker alleles. Dis. Markers15, 269–281 (1999). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Dahl, M., Holmskov, U., Husby, S. & Juvonen, P. O. Surfactant protein D levels in umbilical cord blood and capillary blood of premature infants: The influence of perinatal factors. Pediatr. Res.59, 806–810. 10.1203/01.pdr.0000219122.81734.03 (2006). [DOI] [PubMed] [Google Scholar]
  • 31.Doyle, I. R., Bersten, A. D. & Nicholas, T. E. Surfactant proteins-A and -B are elevated in plasma of patients with acute respiratory failure. Am. J. Respir. Crit. Care Med.156, 1217–1229. 10.1164/ajrccm.156.4.9603061 (1997). [DOI] [PubMed] [Google Scholar]
  • 32.Ratjen, F., Rehn, B., Costabel, U. & Bruch, J. Age-dependency of surfactant phospholipids and surfactant protein A in bronchoalveolar lavage fluid of children without bronchopulmonary disease. Eur. Respir. J.9, 328–333. 10.1183/09031936.96.09020328 (1996). [DOI] [PubMed] [Google Scholar]
  • 33.Sørensen, G. L. et al. Genetic and environmental influences of surfactant protein D serum levels. Am. J. Physiol. Lung Cell. Mol. Physiol.290, L1010–L1017 (2006). [DOI] [PubMed] [Google Scholar]
  • 34.Viklund, E. et al. Current smoking alters phospholipid- and surfactant protein A levels in small airway lining fluid: An explorative study on exhaled breath. PLoS ONE16, e0253825. 10.1371/journal.pone.0253825 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Cheng, G. et al. Increased levels of surfactant protein A and D in bronchoalveolar lavage fluids in patients with bronchial asthma. Eur. Respir. J.16, 831–835 (2000). [DOI] [PubMed] [Google Scholar]
  • 36.Chang, C. C. et al. Second-generation PLINK: Rising to the challenge of larger and richer datasets. Gigascience4, 7. 10.1186/s13742-015-0047-8 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Tingley, D., Yamamoto, T., Hirose, K., Keele, L. & Imai, K. Mediation: R package for causal mediation analysis. J. Stat. Softw.59, 1–38. 10.18637/jss.v059.i05 (2014). [DOI] [Google Scholar]
  • 38.Martono, S., Fatmawati, F. & Mulyanti, S. Risk factors associated with the severity of COVID-19. Malays. J. Med. Sci.30, 84–92. 10.21315/mjms2023.30.3.7 (2023). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Pijls, B. G. et al. Demographic risk factors for COVID-19 infection, severity, ICU admission and death: A meta-analysis of 59 studies. BMJ Open11, e044640. 10.1136/bmjopen-2020-044640 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Maddaloni, L. et al. Could SP-A and SP-D serum levels predict COVID-19 severity?. Int. J. Mol. Sci. 10.3390/ijms25115620 (2024). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Tong, M. et al. Serum surfactant protein D in COVID-19 is elevated and correlated with disease severity. BMC Infect. Dis.21, 737. 10.1186/s12879-021-06447-3 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Doyle, I. R., Nicholas, T. E. & Bersten, A. D. Serum surfactant protein-A levels in patients with acute cardiogenic pulmonary edema and adult respiratory distress syndrome. Am. J. Respir. Crit. Care Med.152, 307–317. 10.1164/ajrccm.152.1.7599839 (1995). [DOI] [PubMed] [Google Scholar]
  • 43.Betsuyaku, T., Kuroki, Y., Nagai, K., Nasuhara, Y. & Nishimura, M. Effects of ageing and smoking on SP-A and SP-D levels in bronchoalveolar lavage fluid. Eur. Respir. J.24, 964. 10.1183/09031936.04.00064004 (2004). [DOI] [PubMed] [Google Scholar]
  • 44.Cheng, I. W. et al. Prognostic value of surfactant proteins A and D in patients with acute lung injury. Crit. Care Med.31, 20–27. 10.1097/00003246-200301000-00003 (2003). [DOI] [PubMed] [Google Scholar]
  • 45.Eisner, M. D., Parsons, P., Matthay, M. A., Ware, L. & Greene, K. Plasma surfactant protein levels and clinical outcomes in patients with acute lung injury. Thorax58, 983–988. 10.1136/thorax.58.11.983 (2003). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Fehrenbach, H. et al. Improved lung preservation relates to an increase in tubular myelin-associated surfactant protein A. Respir. Res.6, 60. 10.1186/1465-9921-6-60 (2005). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Salvioni, L. et al. Surfactant protein D (SP-D) as a biomarker of SARS-CoV-2 infection. Clin. Chim. Acta537, 140–145. 10.1016/j.cca.2022.10.013 (2022). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Takahashi, H. et al. Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent. Am. J. Respir. Crit. Care Med.162, 1109–1114. 10.1164/ajrccm.162.3.9910080 (2000). [DOI] [PubMed] [Google Scholar]
  • 49.Takahashi, H. et al. Diagnostic significance of surfactant proteins A and D in sera from patients with radiation pneumonitis. Eur. Respir. J.17, 481–487. 10.1183/09031936.01.17304810 (2001). [DOI] [PubMed] [Google Scholar]
  • 50.Thorenoor, N., Kawasawa, Y. I., Gandhi, C. K. & Floros, J. Sex-specific regulation of gene expression networks by surfactant protein A (SP-A) variants in alveolar macrophages in response to Klebsiella pneumoniae. Front. Immunol. 10.3389/fimmu.2020.01290 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Thorenoor, N., Kawasawa, Y. I., Gandhi, C. K., Zhang, X. & Floros, J. Differential impact of Co-expressed SP-A1/SP-A2 protein on AM miRNome; sex differences. Front. Immunol. 10.3389/fimmu.2019.01960 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The data presented in the study have been deposited in the ClinVar repository, accession number SCV002506610. Clinical data will be made available upon reasonable request.


Articles from Scientific Reports are provided here courtesy of Nature Publishing Group

RESOURCES